Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

This is Part Two, of our interview with Chat-GPT 5.6. As with Part One, I did not ask GPT questions based on my own interests or, in many cases, not knowing what I thought the answers would or should ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest ...

As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a reality.

Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term catalysts. Click for more on RXRX.

"AI has no consciousness. It likely never will." I saw a story claiming that such a paper was published in Nature.Curious, I ...

AI improves itself and creates even better AI.Such technology is attracting attention as a realistic research topic. It is ...

The Relative Strength Index (RSI), a widely adopted momentum indicator in technical analysis, has recently sparked heated new debates among traders, quantitative analysts and financial market ...

Construct a robust, adaptive system engineered to deliver sustained continuous self-correction and iterative self-renewal ...

Anthropic co-founder Jack Clark has moved his preferred timeline for fully self-improving AI forward from 2028 to 2027. Jack ...

Cost is often what keeps teams from training their own models. Mind Lab combines LoRA post-training, shared base models and distributed optimization, so fewer parameters are updated and less compute ...

Anthropic has filed to raise roughly $100 billion at a $1.5–2 trillion valuation — the largest IPO in history by a wide margin. On Peter ...